Topical amphimatrix with nitroglycerin (mqx-503)    (DrugBank: Nitroglycerin)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
46悪性関節リウマチ0
51全身性強皮症1

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 4,183 trial found

51. 全身性強皮症 [臨床試験数:466,薬物数:536(DrugBank:142),標的遺伝子数:110,標的パスウェイ数:210
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 466 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00419419
(ClinicalTrials.gov)
December 20064/1/2007Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's PhenomenonPhase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's PhenomenonRaynaud's Disease;Scleroderma;Autoimmune DiseasesDrug: Topical AmphiMatrix with nitroglycerin (MQX-503)MediQuest TherapeuticsNULLCompleted18 Years70 YearsBoth80Phase 3United States;Sweden;United Kingdom